Futuregrowth dips its toes into start-up waters once more with an investment in Impulse Biomedical
Impulse’s flagship device, the ZiBiPen, could revolutionise the emergency treatment of life-threatening anaphylaxis. The device was developed by two passionate engineering graduates, Gokul Nair and Giancarlo Beukes, while completing their Master’s degrees in Biomedical Engineering at the University of Cape Town (UCT).
Share this post
The Futuregrowth Development Equity Fund (DEF), on behalf of its clients, has recently invested in a pioneering Cape Town-based biomedical engineering start-up, Impulse Biomedical.
Impulse’s flagship device, the ZiBiPen, could revolutionise the emergency treatment of life-threatening anaphylaxis. The device was developed by two passionate engineering graduates, Gokul Nair and Giancarlo Beukes, while completing their Master’s degrees in Biomedical Engineering at the University of Cape Town (UCT). The company aims to make these and other life-saving healthcare technologies accessible to the developing world.
Impulse is the first pre-revenue startup Futuregrowth has invested in. Amrish Narrandes, Head of Private Equity & Venture Capital at Futuregrowth, explains: “While our focus is normally on late-stage venture capital investments, Impulse Biomedical is an exception. We love Impulse’s ground-breaking technology and products, which, when coupled with the strong founding team, give us confidence that this investment will grow from strength to strength.”
